Saturday 17 October 2026 Export BRTX’s income statement to Excel — free account

Biorestorative Therapies, Inc.

Biorestorative Therapies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $359,700.00, down 10.3% from fiscal 2024. In the quarter to March 2026, revenue fell 7.20%, EPS grew 81.3% and free cash flow fell 35.3%, each against the same quarter a year earlier.

1.54 0.08 +5.48%

Follow BRTX

Alert me

Market cap: $2.0M
P/E: 0.0×
Fwd P/E: −0.8×
Dividend yield: —
F-score: 4/9
Altman Z: −70.97
Beneish M: −7.56
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 2.01

Revenue 0.36

Net Income (11.06)

Free Cash Flow (11.82)

Net Debt (3.59)

Current Ratio 2.35

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.82)

P/S ratio 3.76

P/B ratio 0.45

Past 5Y EPS Growth —

This Y EPS Growth 79.11%

Next Y EPS Growth 12.12%

Next Y revenue growth (13.82%)

Next 5Y EPS Growth 40.67%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 45.38%

10-year low 10-year high

P/B against its own 10 years 95.43%

10-year low 10-year high

EV/FCF against its own 10 years 7.11%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	11	11	3	4
Receivables	0	0	0	0
Inventory	—	—	—	—
Other	—	—	—	—
	11	11	3	4

	2023	2024	2025	Q'26
Payables	0	0	1	1
ST’ Debt	—	—	—	—
Other	2	3	1	—
	3	4	4	2

Compound Annual Growth %

	10y	5y	3y
Sales	(5.43%)	36.11%	44.27%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	(71.76%)

Revenue $m

	Jun	Sep	Dec	Year
’26	—	—	—	—
’25	0	0	0	0
’24	0	0	0	0
’23	0	0	0	0
’22	0	0	0	0
’21	0	0	0	0
’20	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	—	—	—	—
’25	(3)	(3)	(3)	(2)	(11)
’24	(2)	(2)	(2)	(2)	(8)
’23	(2)	(1)	(1)	(2)	(6)
’22	(2)	(1)	(1)	(2)	(6)
’21	(1)	(1)	(1)	(1)	(3)
’20	0	0	(1)	(1)	(2)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	—	—	—	—
’25	(3)	(3)	(3)	(2)	(11)
’24	(2)	(2)	(2)	(2)	(8)
’23	(2)	(1)	(1)	(2)	(7)
’22	(2)	(1)	(1)	(2)	(6)
’21	(1)	(1)	(1)	(1)	(3)
’20	0	0	(1)	(1)	(2)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(2.40)	—	—	—	—
’25	(12.80)	(6.00)	(6.60)	(6.40)	(31.60)
’24	(6.60)	(10.00)	(2.60)	(4.00)	(23.20)
’23	(30.60)	(29.38)	7.74	(11.40)	(49.39)
’22	(27.40)	(25.60)	(25.60)	(23.60)	(102.20)
’21	(428.86)	(102.08)	(99.80)	(139.80)	(746.00)
’20	(524.32)	120.22	(41.95)	(125.15)	(571.20)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	10,440.00	10,000.00	1,960.00	18.80	0.40	3.80	2.46	1.41	1.03	0.98	Analyst estimates 2026–2028 Powerpack
	High	17,920.00	20,040.00	16,000.00	3,680.00	185.60	132.00	5.98	7.13	3.67	2.55
People
People	Employees	11	9	9	6	5	7	10	11	11	14
	Revenue/emp, $m	0.00	0.01	0.01	0.02	0.02	0.01	0.01	0.01	0.04	0.03
Income, $m
Income, $m	Revenue	0	0	0	0	0	0	0	0	0	0
	Gross margin, %	99.73	100.00	100.00	100.00	100.00	100.00	100.00	100.00	92.99	93.38
	EBT	(9)	(9)	(13)	(15)	(11)	(44)	(18)	(10)	(9)	(14)
	EBT margin, %	(23,726.10)	(11,660.12)	(11,277.30)	(11,267.62)	(14,639.87)	(96,311.52)	(15,438.06)	(7,145.20)	(2,239.25)	(3,959.41)
	Net income	(9)	(9)	(13)	(15)	(11)	(44)	(18)	(10)	(9)	(14)
	Depreciation	1	1	3	4	1	1	0	0	0	0
Per share, $
Per share, $	Revenue	364.00	810.00	1,110.00	433.33	3.91	0.77	0.66	0.69	1.03	0.80
	Earnings	(140,000.00)	(116,000.00)	(109,333.30)	(43,835.61)	(461.62)	(746.00)	(102.20)	(49.39)	(23.20)	(31.60)
	Cash flow	(50,027.00)	(38,538.00)	(51,046.00)	(23,062.33)	(99.71)	(56.06)	(32.69)	(30.49)	(21.20)	(23.99)
	Capex	(1,888.00)	(36.00)	(129.00)	(118.67)	0.00	(0.52)	(2.43)	(0.81)	(0.27)	(0.26)
	Free cash flow	(51,915.00)	(38,574.00)	(51,175.00)	(23,181.00)	(99.71)	(56.58)	(35.12)	(31.30)	(21.47)	(24.25)
	Book value	(50,003.00)	(68,366.00)	(86,410.00)	(42,587.33)	(67.59)	363.59	87.52	47.44	21.98	0.79
	Shares, m	0	0	0	0	0	0	0	0	0	0
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	37.36	18.27	3.24	0.05	7.06	5.60	4.11	2.49	1.38	1.48
	P/B	0.00	0.00	0.00	0.00	0.00	0.01	0.03	0.04	0.07	1.55
	EV/Sales	44.67	15.09	6.90	1.24	22.72	(447.35)	(117.42)	(72.10)	(24.90)	(6.20)
	EV/FCF	(0.31)	(0.31)	(0.15)	(0.02)	(0.87)	6.06	1.91	1.35	1.04	0.18
Cash, $m
Cash, $m	Operating cash flow	(5)	(4)	(5)	(7)	(2)	(3)	(6)	(6)	(8)	(11)
	Capex	0	0	0	0	—	0	0	0	0	0
	Free cash flow	(5)	(4)	(5)	(7)	(2)	(3)	(6)	(7)	(8)	(11)
Balance, $m
Balance, $m	Working capital	(6)	(8)	(9)	(14)	2	21	15	9	7	(1)
	Total debt	0	0	1	1	4	0	0	—	—	—
	Net debt	0	0	0	1	1	(21)	(15)	(11)	(11)	(3)
	Shareholders’ equity	(5)	(7)	(9)	(13)	(1)	22	16	10	9	0
Returns, %
Returns, %	ROA	(480.19)	(565.79)	(848.38)	(1,101.88)	(387.82)	(330.62)	(95.12)	(71.73)	(72.15)	(174.11)
	ROIC	0.00	0.00	0.00	0.00	0.00	(2,159.78)	(1,095.29)	0.00	0.00	0.00
	ROE	193.88	159.58	161.75	136.79	159.81	(437.56)	(98.91)	(80.73)	(97.03)	(321.48)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
KAPA Kairos Pharma, Ltd.	$2.3M	— (loss-making)	—	—	n/m	−25.71% (below 0%: shrinking)	—	0.00%	Compare
VRAX Virax Biolabs Group Limited	$2.2M	— (loss-making)	— (loss-making)	—	−855.56% (below 0%: shrinking)	+32.24% (above 0%: growing)	(53.57%)	0.00%	Compare
CLSDQ Clearside Biomedical, Inc.	$2.2M	— (loss-making)	— (loss-making)	−80.64% (below 0%: shrinking)	n/m	+8.15% (above 0%: growing)	100.00%	(3,502.49%)	Compare
BRTX Biorestorative Therapies, Inc.	$2.0M	— (loss-making)	— (loss-making)	−7.20% (below 0%: shrinking)	n/m	−35.26% (below 0%: shrinking)	68.10%	(14,593.53%)
PPBT Purple Biotech Ltd. Sponsored ADR	$2.0M	— (loss-making)	— (loss-making)	—	n/m	−62.10% (below 0%: shrinking)	0.00%	0.00%	Compare
OGEN Oragenics, Inc.	$2.0M	0.4×	— (loss-making)	−75.33% (below 0%: shrinking)	n/m	−66.37% (below 0%: shrinking)	100.00%	0.00%	Compare
SILO Silo Pharma, Inc.	$1.9M	— (loss-making)	18.4×	0.00%	n/m	+39.17% (above 0%: growing)	(15.00%)	0.00%	Compare
GNPX GENPREX	$1.9M	0.0×	—	—	n/m	−32.98% (below 0%: shrinking)	0.00%	0.00%	Compare
TRVN Trevena, Inc.	$1.8M	— (loss-making)	— (loss-making)	+57.22% (above 0%: growing)	n/m	+49.55% (above 0%: growing)	59.72%	(1,970.67%)	Compare
Median of peers	$2.0M	—	—	−37.66%	—	−8.78%	0.00%	0.00%

All 614 Biotechnology stocks →

Biorestorative Therapies, Inc. (BRTX) key facts

Concern: Biorestorative Therapies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $359,700.00, down 10.3% from fiscal 2024.
Biorestorative Therapies, Inc. (BRTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, BRTX traded at $1.54, a market capitalization of $2.0 million.
Return on equity was −321.5% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −70.97 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.